tbuckley/cabot-search huggingface dataset:
Medical repatriation at end of life: Barriers, facilitation, and fulfillment—A case-series study at a New York public hospital.
Authors: Nagashree Seetharamu, Hilary Y. Ma, Robert Smeltz, Jessica Schindewolf, Mariam Empalmado, Susan E. Cohen
Journal: Journal of Clinical Oncology (2014)

141 Background: Foreign-born cancer patients frequently desire to return to their home country at the end of life. However, many barriers can make this process challenging. We herein present our recent experience with such patients. Methods: We reviewed charts of terminal cancer patients (pts) who traveled to their homeland at the end of life. Pts’ age, diagnoses, co-morbidities, prior cancer-directed treatment, predicted survival, symptoms, code status, admissions within 4 weeks of travel, oxygen need were noted. Interval between decision to travel and travel date, events during travel, and feedback from families, if available were collected. Results: 17 charts (11 female, 6 male) were analyzed. Mean age was 60 years and the most common diagnosis was thoracic malignancy (70%, 12 pts). All pts had disseminated cancer and had received an average of 2 lines of cancer-directed therapy. All had progressive cancers with expected survival &lt;6 months. All were under the care of medical oncologists, palliative care and social work. The mean interval between decision to travel and travel date was 9 days. 8 were hospitalized at least once in the 4 weeks prior to the day of travel and 6 were cared for as inpatients immediately prior to travel. 11 pts were receiving opioids for pain and 3 were oxygen-dependent. 10 had documented discussions regarding resuscitation and 9 were discharged with New York State out-of –hospital DNR forms. All were discharged with medical records, medication supply and provider contact information. Mean travel distance was 4,099 miles. Provider concerns for decompensation during travel included brain herniation (2), spinal cord compression (3), bleeding (1), and sepsis (2). 16 pts successfully completed their journey. 1 pt died en-route prior to boarding the aircraft. 12 pts/families provided positive feedback about the experience. Conclusions: Return to homeland is an important goal for many terminally ill cancer pts and should be a routine part of end-of-life discussions. Medical repatriation can be accomplished when conducted in a planned, well-coordinated manner. Insights from this review can help us create guidelines that can be readily applied to specific scenarios.
480TiP IMpower110: Phase III study on 1L atezolizumab (atezo) in PD-L1–selected chemotherapy (chemo)-naive NSCLC patients (pts)
Authors: F. De Marinis, J. Jassem, D.R. Spigel, S. Lam, S. Mocci, A. Sandler, A. Lopez-Chavez, Y. Deng, G. Giaccone, R.S. Herbst
Journal: Annals of Oncology (2016)
RAS/AKT pathway mutations as predictive biomarkers in patients with colorectal cancer treated with the exportin 1 (XPO1) inhibitor selinexor (SEL) – inhibition of nuclear-cytoplasmic translocation of p27 as a mechanism of anti-tumour activity
Authors: V.Y.M. Heong, P. Koe, W.P. Yong, R. Soo, C.E. Chee, A. Wong, Y.L. Thian, R. Sundar, J.S. Ho, A. Gopinathan, S.C. Lee, B.C. Goh, D. Tan
Journal: Annals of Oncology (2016)
Assessing the potential cost-effectiveness of retesting IHC0, IHC1-positive, or FISH-negative early-stage breast cancer patients for HER2 status.
Authors: L. P. Garrison, D. Lalla, M. G. Brammer, B. Wang, J. Babigumira, E. A. Perez
Journal: Journal of Clinical Oncology (2011)

6133 Background: FISH or IHC tests are commonly used to assess HER2 status: patients whose tumors are IHC 0, IHC 1+ or FISH negative are typically not retested to assess HER2 overexpression. Recent evidence shows that adjuvant patients can have tumors that are HER2+ by one test and HER2- by the 2nd and still benefit from treatment with trastuzumab (T). Also, the product label for T recommends not relying on a single test to assess HER2 status. This analysis evaluates the likely cost-effectiveness of assessing HER2 status in women with early stage breast cancer by implementing a strategy of expanded reflex testing. Methods: We developed a decision-analytic model to assess the incremental cost-effectiveness ratio (ICER) of reflex testing strategies from a US payer perspective. Expanded reflex testing is defined as retesting patients whose tumors are IHC0, IHC1+ or FISH negative on their first test. In the base case, it was assumed that 80% of patient tumors are initially IHC-tested, and 20% FISH-tested. Estimated testing outcomes for IHC and FISH with and without retesting were based on published meta-analyses. Key inputs from the literature included: cost of tests—IHC ($89) and FISH ($482); cost of T treatment ($45,000); life years gained (1.84); and quality-adjusted life years (QALYs) gained with adjuvant T (1.70). In the base case, we estimated that 3.1% of the women who received expanded reflex testing would be found to be HER2 positive and receive T treatment. Sensitivity analysis varied this between 1% and 8%. Results: In the base case, the projected ICER is $34,000/QALY. This varied from $50,000 to $29,000, if we assumed 1% to 8% of patients retested were then HER2+, respectively. This strategy would result in 2,000-17,000 additional women receiving T annually. Conclusions: The cost-effectiveness ratio for expanded reflex testing is below commonly cited thresholds for cost-effectiveness even if only 3% of the retested population were classified HER2+ on retesting. This improves as the proportion of patients who are classified as HER2+ upon retesting increases. Retesting patients who are IHC0, IHC1+ with FISH or those FISH negative with IHC is projected to be a cost-effective clinical strategy.
Divergent Point of Developmental Cell Fate of Common Precursor for Cardiomyocyte and Hemangioblast Is Accompanied by the Presence or Absence of Expression of PDGFRalpha and Flk-1.
Authors: Hirokazu Hirata, Yoshinobu Murakami, Yosuke Tanaka, Kayoko Inoue, Masakazu Ishikawa, Masataka Sasada, Takayuki Asahara, Shin Kawamata
Journal: Blood (2004)
GENT-46. REDUCED p16 EXPRESSION IN A MURINE MODEL OF H3.3K27M EXPRESSING DIPG SENSITIZES CELLS TO CDK4/6 INHIBITION
Authors: Francisco Cordero, Guo Hu, Christine Hoeman, Oren Becher
Journal: Neuro-Oncology (2016)

Diffuse intrinsic pontine glioma (DIPG) remains an incurable pediatric tumor with a median survival of less than one year and no approved chemotherapy. Recent studies using DIPG tissue revealed prevalent H3.3K27M mutations restructure the epigenome. The histone mutation causes globally reduced H3K27me3 repression with localized peaks including at the p16 promoter. The p16 tumor suppressor is a CDK4/6 inhibitor that regulates proliferation and is commonly deleted in many cancers but rarely in DIPG. Therefore, CDK4/6 inhibition treatment has not been considered. Because of localized gains in H3K27me3 we sought to explore the epigenetic silencing of p16 and its potential as a novel therapeutic avenue for DIPG. We asked 1) whether H3.3K27M expression reduces p16 levels leading to increased proliferation and 2) whether H3.3K27M cells are sensitized to CDK4/6 inhibition. We generated high-grade murine brainstem gliomas through targeted retroviral infection to overexpress the oncogenic driver PDGFB, knockout p53, and overexpress either H3.3K27M-GFP or H3.3WT-GFP. In both RNA-Seq on our tumors as well as qPCR on cultured tumorspheres we see decreased p16 expression. This corresponded with significantly increased proliferation of H3.3K27M cells by BrdU incorporation. We used ChIP-qPCR for H3K27me3 at the p16 promoter and found a significant increase of H3K27me3 in H3.3K27M expressing cells. We inhibited the histone methyltransferase EZH2 with 1uM GSK343 and saw that although treatment significantly reduced H3K27me3 levels at the p16 promoter of both wild-type and H3.3K27M lines, proliferation and p16 levels were unaffected. However, when we treated our lines with palbociclib, a known CDK4/6 inhibitor, we found H3.3K27M lines had a significantly lower IC50 compared to controls (180nM and 1.5uM respectively). These data suggest H3.3K27M reduces p16 levels and sensitizes cells to CDK4/6 inhibition. All together this highlights the p16 pathway as a promising pathway for development of efficacious treatment for DIPG patients harboring H3.3K27M mutations.
A New Liquid 10% Intravenous Immunoglobulin (IVIG) Administered with 15-Minute Titration Periods Allows Shorter Infusion Durations and Tolerability Similar to a 5% Formulation
Authors: Mark R. Stein, Kelly Farnan, Danielle Eufrasio, Miranda Norton
Journal: Journal of Allergy and Clinical Immunology (2017)
A biomarker-guided first-in-human trial of subcutaneous ALM201 in patients with solid tumours
Authors: A. El-Helali, R. Plummer, G. Jayson, V. Coyle, C. Rogers, M. D'Arcangelo, D.M. Graham, Y. Drew, A. Clamp, J. McCann, A. McCavigan, L. Knight, N. McCabe, K. Keating, R. Dyer, T. Harrison, P. Harkin, T. Robson, R. Kennedy, R. Wilson
Journal: Annals of Oncology (2016)
Time-to-treatment failure (TTF) with first-line afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) advanced non-small-cell lung cancer (NSCLC): Randomized phase IIb LUX-lung 7 (LL7) trial
Authors: M. Schuler, E.-H. Tan, K. O'Byrne, L. Zhang, M. Boyer, T.S.K. Mok, V. Hirsh, J.C.-H. Yang, K.H. Lee, S. Lu, Y. Shi, S.-W. Kim, J. Laskin, D.-W. Kim, C. Dubos Arvis, K. Kölbeck, D. Massey, J. Fan, L. Paz-Ares, K. Park
Journal: Annals of Oncology (2016)
Freeze-Drying Human Red Blood Cells: Effect of Hematocrit and Composition of the Freeze-Drying Medium on Red Cell Survival.
Authors: Gyana R. Satpathy, Zsolt Torok, Mitali Banerjee, Rachna Bali, Erika Little, John H. Crowe, Nelly M. Tsvetkova, Fern Tablin
Journal: Blood (2004)
Is second-line targeted therapy beneficial in patients (pts) with differentiated thyroid cancer (DTC) after first-line sorafenib (SOR) failure?
Authors: Ramona Dadu, Catherine E Devine, Mike Hernandez, Naifa Busaidy, Steven Waguespack, Anita Ying, Mouhammed Amir Habra, Sonali Thosani, Mimi I-Nan Hu, Maria E. Cabanillas
Journal: Journal of Clinical Oncology (2013)

e17016 Background: SOR has demonstrated efficacy in phase II trials but responses are not durable. 2nd line therapy is used in clinical practice however there are no data showing clinical benefit with this approach. We sought to determine if 2nd line targeted therapy was beneficial after SOR failure. Methods: Adult pts with DTC treated with 1st line SOR for &gt;3 months were included. We compared overall survival (OS) in pts who received only 1st line SOR (grp 1) with pts treated with 2nd line therapy after 1st line SOR failure (grp 2). OS was defined as time after SOR failure until death. SOR failure was defined as discontinuation due to progression or intolerable toxicity. Results: We identified 62 DTC pts from 2006-2012 who were treated with 1st line SOR. 10 pts in grp 1 were excluded due to missing data, secondary unrelated cancers and &lt;3 mo on SOR. We included 52 pts: 31 in grp 1 and 21 in grp 2. Baseline characteristics were similar between groups (Table). FTC was more frequent in grp 2. 2nd therapy included sunitinib, pazopanib, vemurafenib, and other investigational drugs. Median time on treatment with 2nd line therapy was 14.5 mo. Median OS in grp 1 and grp 2 was 6 and 50 mo, respectively (p=0.002). After excluding pts for death &lt;3 mo after SOR end, median OS was 20 and 50 mo; there was a trend toward significance (p=0.07). Response and updated analysis will be reported at the meeting. Conclusions: Our study shows that pts receiving 2nd line therapy after SOR failure had a long OS despite more pts with FTC in this group. Acknowledging the limitations of a retrospective study, we conclude that in DTC pts, salvage targeted therapy after SOR failure appears to be beneficial and a promising strategy. [Table: see text]
Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells
Authors: Cody Paiva, Claire Godbersen, Stephen E Spurgeon, Sreesha Srinivasa, Jennifer R Brown, Alexey V Danilov
Journal: Blood (2015)
Clinical Features of the Asthmatic Frecuent-Users of the Emergency Department in a Tertiary Hospital
Authors: Beatriz Pola Bibian, Gemma Vilà-Nadal, Javier Dominguez Ortega, Nataly Cancelliere Fernandez, Pilar Barranco Sanz, Santiago Quirce Gancedo
Journal: Journal of Allergy and Clinical Immunology (2017)
Characterising the Burden of Chronic Lymphocytic Leukemia in Fludarabine-Ineligible Patients in Spain, Italy, and the United Kingdom (UK): A Retrospective Observational Study
Authors: Julio Delgado, Davide Rossi, Francesco Forconi, Edith Schodl, Karissa M Johnston, Jane Raine, Amin Haiderali
Journal: Blood (2014)
Hypersensitivity Reactions to Proton Pump Inhibitors (PPIs) – One Year's Experience of the Allergy Department at the “Professor Doctor Octavian Fodor” Regional Institute of Gastroenterology and Hepatology (RIGH), Cluj-Napoca, Romania
Authors: Carina Petricau, Elena Mustea, Irena Nedelea, Diana M. Deleanu
Journal: Journal of Allergy and Clinical Immunology (2017)
Cancer survivorship algorithms as clinical tools for primary care providers.
Authors: Guadalupe R. Palos, Katherine Ramsey Gilmore, Paula A. Lewis-Patterson, Maria Alma Rodriguez
Journal: Journal of Clinical Oncology (2016)

100 Background: Clinical decision tools (CDTs) such as survivorship algorithms may be valuable resources for primary care providers who provide post-treatment care for cancer survivors. Our objective was to assess providers’ perceptions, adoption, and satisfaction with clinical practice algorithms tailored to site-specific cancer survivorship clinics. Methods: Eligible providers were those assigned to one of 9 site-specific survivorship clinics, (breast, colorectal, genitourinary, gynecology, head and neck, lymphoma, melanoma, stem cell transplant, and thyroid). Potential respondents were invited to participate by emails. Voluntary return of the survey indicated a provider’s informed consent. Providers had the choice to participate by clicking on a link embedded in an email. Once the link was activated, the user was taken to a 10-item survey with questions asking about the usability, awareness, and satisfaction with the algorithms specific to their clinic. Descriptive statistics (i.e. frequencies and percentages) were used to summarize the responses. Results: Of 35 providers assigned in the survivorship clinics, 18 responded resulting in a 51% response rate. The majority of respondents (94.4%) were aware of the survivorship algorithms specific to their clinic. Over 75% reported using the algorithms occasionally (16.7%), frequently (33%) and always (33.3%). The major barrier to using the algorithms was a lack of awareness on to access the algorithms. Over half of the providers (55.6%) preferred using the digital versions of the algorithms. 68% strongly agreed the algorithms were practical to use and implement in their clinical setting. The majority of providers’ reported being satisfied (62.5%) or very satisfied (25.0%) with the algorithms tailored to their site specific clinic. Conclusions: Survivorship practice algorithms were perceived as useful clinical resources to deliver coordinated care to cancer survivors with diverse cancer diagnoses. Future work is needed to determine the impact of the algorithms on providers’ practice with cancer survivors.
A multicenter phase 4 geriatric assessment directed trial to evaluate gemcitabine +/- nab-paclitaxel in elderly pancreatic cancer patients (GrantPax)
Authors: N. Härtel, J. Chi-Kern, J. Betge, S. Belle, N. Schulte, M. Maenz, U. Wedding, M. Ebert
Journal: Annals of Oncology (2016)
Pathway Analysis of Molecular Mutations Can Modify Morphologic, Cytogenetic and Prognostic Risk Stratification Schemes in Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes/Myeloproliferative Neoplasms (MDS/MPN), and Secondary Acute Myeloid Leukemia (AML)
Authors: Edy Hasrouni, Valeria Visconte, Ali Tabarroki, Heesun J. Rogers, Fabiola Traina, Anna Jankowska, Yang Liu, Betty K. Hamilton, Manoj Bupathi, Hideki Makishima, Andres Jerez, Edward A. Copelan, Anjali Advani, Michael A McDevitt, Matt Kalaycio, Yogen Saunthararajah, Mikkael A. Sekeres, Jaroslaw P. Maciejewski, Ramon V. Tiu
Journal: Blood (2012)
Is laser biostimulation safe even when performed in neoplastic fields?
Authors: Giulia Ottaviani, Serena Zacchigna, Margherita Gobbo, Katia Rupel, Alessandra Guglielmi, Rossana Bussani, Roberto Di Lenarda, Matteo Biasotto
Journal: Journal of Clinical Oncology (2015)

3 Background: Oral mucositis and skin dermatitis induced by oncological therapies can impair patients’ functional capacity and quality of life. Laser therapy has been proposed as an effective treatment for both conditions, although with an unclear mechanism. Laser irradiation seems to enhance mitotic activity of epithelial cells, fibroblasts and collagen fibres, but are we sure that it does not stimulate neoplastic cells as well? Two different mice models have been ad hoc created to investigate whether laser therapy can be safely performed even on neoplastic areas. Methods: First model: 4-NQO chemical carcinogen was administered to 50 mice for 16 weeks. During the 17 th week, 25 mice were subdued to 4 daily laser therapy sessions (970nm, 2.5W/cm2, duty cycle 50%, 2Hz, 180J/cm2), while 25 mice were used as controls. Afterwards, animals were sacrificed to perform histological analysis. Second model: Melanoma cells were implanted in 48 mice at the dorsal subcutaneous level. A tumour mass developed at the site of injection and mice were homogeneously divided into 4 groups according to tumour size: 3 groups were subject to different laser protocols (660nm, 100mW/cm2, CW, 3J/cm2; 800nm, 1W/cm2, CW, 20J/cm2 and 970nm, 60mW/cm2, CW, 6J/cm2) for 4 consecutive days, while the fourth group was used as control. All animals were euthanized to measure tumour volume and weight, and to quantify tumour invasiveness through immunohistochemistry (CD68 and Melan-A). Results: First model: the number/extension of dysplastic/neoplastic areas did not increased after laser irradiation (p&lt;0.05). Unexpectedly, while carcinomas are normally surrounded by dysplastic tissue displaying different degrees of cells alterations, laser treated carcinomas appeared as insulated lesions surrounded by healthy epithelium. Second model: tumour growth and weight and neoplastic cells infiltration were lower in all laser groups compared to the controls (p&lt;0.05). Conclusions: The above-presented results may also prove that laser therapy can be safely performed to treat oral mucositis and skin dermatitis even in patients with active oncological disease. A key-role of the immune system may explain the peculiar behaviour of carcinomas and melanomas in response to laser irradiation.
Prevalence and Prognostic Significance of FLT3 Mutations in Acute Myeloid Leukemia: Association of ITDs with Poor Outcome in Patients with Normal Cytogenetics.
Authors: Michela Palmisano, Emanuela Ottaviani, Tiziana Grafone, Nicoletta Testoni, Stefania Paolini, Michela Rondoni, Michele Baccarani, Giovanni Martinelli
Journal: Blood (2006)
Dose escalation of low molecular weight heparin to manage recurrent venous thromboemblic events despite systemic anticoagulation in cancer patients
Authors: M. Carrier, G. Le Gal, R. Cho, S. Tierney, A. Y. Lee
Journal: Journal of Clinical Oncology (2009)

e20580 Background: Cancer patients with venous thromboembolism (VTE) are at high risk of recurrent VTE. The rate of recurrent VTE ranges from 9 to 17% despite therapy with low molecular weight heparins (LMWH) or vitamin K antagonists (VKA) respectively. To date, no published evidence is available to guide treatment of cancer patients with recurrent VTE. We sought to evaluate the benefit and risk of LMWH dose escalation in cancer patients with recurrent VTE. Methods: Retrospective cohort study was conducted in consecutive cancer outpatients referred for management of an objectively confirmed, symptomatic, recurrent VTE while receiving an anticoagulant. Patients were treated with either dose escalation of weight-adjusted LMWH in patients already anticoagulated with LMWH or initiation of a therapeutic dose LMWH in patients who were taking a VKA. All patients were followed for a minimum of 3 months after the index recurrent VTE. Results: Seventy cancer patients with a recurrent VTE despite ongoing anticoagulation were included. The median time between the initial VTE to the index recurrence was 3.5 months (range 0.3 to 193 months). At the time of the recurrence, 67% of patients were on LMWH, while 33% were on VKA. Following the treatment with either dose escalation or initiation of LMWH, a total of 6 patients (8.6%; 95% confidence interval (CI): 4.0% to 17.5%) had a second recurrent VTE during the three-month follow-up period, at an event rate of 9.9 per 100 patient-years (95% CI: 2.0 to 17.8). The median time between the index and second recurrent VTE was 1.9 months (range 0.6 to 3.0 months). One patient (1.4%; 95% CI: 0.3% to 7.7%), or 1.6 per 100 patient-years (95% CI: 0.0% to 4.8%) of follow-up, had a major bleeding event. The median time between the index recurrent VTE to death was 11.4 months (range 0 to 83.9 months). Conclusions: Patients with recurrent VTE have a poor prognosis. Escalating the dose of LMWH can be effective for treating cases that are resistant to standard, weight-adjusted doses of LMWH or a VKA. [Table: see text]
A phase I/II study of concurrent nab-paclitaxel, carboplatin, and IMRT for locally advanced squamous cancer of the head and neck (LASCCHN).
Authors: Roy B. Tishler, Jochen H. Lorch, David J Sher, John Ross Clark, Annie W Chan, Margaret Suda, Tracy A. Balboni, Paul M. Busse, Robert I. Haddad, Lori J. Wirth
Journal: Journal of Clinical Oncology (2012)

5579 Background: We studied escalating doses of weekly nab-paclitaxel (Abraxane, AB) combined with weekly carboplatin (CP) and daily IMRT in patients with LASCCHN to determine the safety and optimal dosing of AB. The favorable biodistribution of AB, an albumin bound formulation of paclitaxel, may allow for intensified locoregional treatment without increasing normal tissue toxicity. Methods: An AB dose escalation was performed, initially using concurrent weekly CP (AUC = 1.5), Erbitux (ER) and daily IMRT to 70 Gy. After ER was dropped, dose escalation of AB from 20 mg/m2 to 50 mg/m2 was performed in 10 mg/m2 increments using a 3 + 3 study design. Results: A total of 28 patients have enrolled and all have completed treatment. Patients ranged in age from 42 to 72 years old (median = 59), with follow up from 3 to 48 months (median = 25). Most patient had oropharyngeal primaries (n=22) and stage III (n=8) or IV (n=20) disease; 18 were HPV+, 6 HPV- and 4 unknown. Initially 6 patients received weekly AB (20 mg/m 2 ), ER and CP, but ER was dropped due to greater than anticipated mucositis and dysphagia. Subsequently, 3 patients each received CP with AB at 20, 30 and 40 mg/m 2 weekly and a total of 13 received CP with AB at 50 mg/m 2 . The median radiation dose is 70 Gy and the median number of weekly chemotherapy cycles is 7. The primary toxicities were Grade 3 dysphagia, mucositis and dermatitis in 24 of 28 patients. Only 3 (of 28) PEG tubes remain at 4, 6 and 14 months. No DLTs were observed at any dose level. There have been 5 recurrences, with 4 being local-regional. Two patients have died of disease and 26 are alive. Conclusions: Concurrent AB, CP, and IMRT is a safe chemoradiotherapy combination in LASCCHN with early data demonstrating feasibility and efficacy.
Initial Treatment of CD20+ Lymphocyte Predominant Hodgkin Lymphoma with Chemotherapy and the Monoclonal Antibody Rituximab-Mabthera Is Effective and Well Tolerated - Case Report.
Authors: Sonja G. Genadieva-Stavrik, Lubomir Ivkovski, Aleksandra Pivkova, Lidija Cevreska
Journal: Blood (2006)
PNAS-2’s Subcullar Location in Leukemic Cell Is Abnormal and Its Relation with Leukemogenesis.
Authors: Hai-Rong Wang, Fang-Yuan Chen, Hua Zhong, Ji-Hua Zhong, Fei Xiao, Jian-Yi Zhu, Jie-Yin Han, Ren-Rong OuYang
Journal: Blood (2007)